JNJ Stock Recent News
JNJ LATEST HEADLINES
Jared Holz, Mizuho, joins 'Fast Money' to talk headwinds to the pharma sector.
NEW ORLEANS--(BUSINESS WIRE)--A jury has awarded $3 million to the family of Jeanine Henderson, a 72-year-old mother from New Orleans who died from mesothelioma, a rare and incurable cancer caused by asbestos exposure, after a lifetime of using Johnson & Johnson's Baby Powder. After a two-month trial, attorneys from Dean Omar Branham Shirley successfully proved that Ms. Henderson's daily use of the talc-based powder was directly linked to her illness. The legal team also presented clear evi.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson today announced the expansion of its efforts to champion the nursing workforce and improve access to quality care for communities around the world. These efforts are part of J&J CareCommunity, a new social impact platform that focuses the resources and expertise of J&J and J&J Foundation to support nurses at every step of their career journey and strengthen health systems worldwide. The expansion aims to help address the gl.
Stocks have rebounded sharply off their early-April lows, but macro risks persist. Dividend stocks have largely outperformed so far this year. We profile a pair of blue chips that recently announced dividend hikes, which has turned out to be a broader Q2 theme.
There's no such thing as a safe stock, but these low-volatility names stand up relatively well in shaky markets.
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
Both JNJ and ABBV expect their sales and profits to improve in 2025.
President Donald Trump signed an executive order to incentivize drug manufacturing in the U.S. The order comes ahead of Trump's planned tariffs on pharmaceuticals imported into the U.S.
Most of the MedTech players have adjusted their 2025 forecasts in response to rising tariff pressure.
TREMFYA® subcutaneous induction demonstrates significant rates of clinical remission and endoscopic improvement at Week 24 in ulcerative colitis Findings build on recent FDA-approval of both routes of administration for induction therapy with TREMFYA® in Crohn's disease SAN DIEGO , May 5, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adults with moderately to severely active ulcerative colitis (UC). The ASTRO Week 24 data build on the Week 12 SC induction data that showed statistically significant and clinically meaningful improvements compared to placebo across all clinical and endoscopic measures consistent with the U.S. Food and Drug Administration (FDA)-approved intravenous (IV) induction regimen evaluated in this population, in the Phase 3 QUASAR study.1,2 TREMFYA® is the first and only IL-23 inhibitor to demonstrate robust results with a full